Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Inactivated, Split-Virion Influenza Virus · 4 trials · 5 indications
Information concerning the safety of Fluzone® vaccine 2007-2008 formulation.
GMTs and their 95% Confidence Interval are presented for each of the 3 antigens in the Fluzone® Vaccine 2007-2008 formulation.
| Arm | Type | Description |
|---|---|---|
| Study Group 1 | EXPERIMENTAL | - |
| Study Group 2 | ACTIVE_COMPARATOR | - |
| Study Group 3 | EXPERIMENTAL | Elderly, age 60 to 85 years |
| Study Group 4 | EXPERIMENTAL | Elderly, age 60 to 85 years |
| Study Group | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Inactivated, split-virion influenza virus | BIOLOGICAL | 0.1 mL, Intradermal. 2 vaccinations 12 months apart |
| Inactivated, split-virion, influenza vaccine | BIOLOGICAL | 0.1 mL, Intradermal |
| Inactivated, split-virion influenza vaccine | BIOLOGICAL | 0.1 mL, Intradermal |
Inclusion Criteria: * Able to attend all scheduled visits and to comply with all trial procedures. * Subject with renal transplant for at least 6 months. * Subject with stable renal function, i.e. with a variation of creatinin value \< 20% and with a creatinin clearance estimated according to Cockr...
Inactivated, Split-Virion Influenza Virus is an investigational vaccine being developed for influenza and orthomyxoviridae infections. It is designed to prevent illness caused by influenza viruses. The vaccine is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Sanofi (ticker: SNY) is developing Inactivated, Split-Virion Influenza Virus. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in various populations, including adults, elderly subjects, and renal transplant recipients.
Inactivated, Split-Virion Influenza Virus is in Phase 2 clinical development. It is an investigational vaccine and has not received regulatory approval. Four Phase 2 trials have been completed, with a total enrollment of 4,787 participants across multiple countries.
Inactivated, Split-Virion Influenza Virus has completed four Phase 2 trials: NCT00524940, NCT00606359, NCT00703651, and NCT00776438. These trials assessed safety and immunogenicity in healthy volunteers and specific populations, including renal transplant subjects, across the United States, France, Belgium, Czechia, and Lithuania.
Inactivated, Split-Virion Influenza Virus is compared against Fluzone and Vaxigrip in clinical trials, but it is not stated to be the same product. The trials reference these as comparators or alternative vaccines, indicating they are distinct formulations being evaluated for immunogenicity.